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540 CorrespondenceRe. ‘Remote Ischemic Preconditioning to Reduce Contrast-
Induced Nephropathy: a Randomized Controlled Trial’
We read with great interest the paper by Menting et al.
about the use of remote ischemic preconditioning (RIPC) to
reduce contrast medium induced nephropathy (CIN) in pa-
tients at risk of CIN.1 Their results in a group at high risk of
CIN are in line with results from Er et al. who showed that
use of such a procedure could reduce CIN in high risk pa-
tients. Er et al. identiﬁed CIN in 20 patients in their control
group, but only six in their RIPC group (p ¼ .002).2 In both
studies, RIPC was performed as an adjunct to hydration.
However, in our opinion, the role of hydration requires
further discussion, especially where different hydration
protocols are performed. Zarbock et al. showed that RIPC
alone reduced the rate of acute kidney injury and the use of
renal replacement therapy among high risk patients un-
dergoing cardiac surgery.3 Therefore, the question remains
whether or not RIPC should be used as an adjunct or alone?
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We thank Drs. Koch and colleagues for their comments.
Their question, if remote ischemic preconditioning is suf-
ﬁcient on its own to prevent contrast medium induced
nephropathy (CIN), cannot be answered with current
literature data. In patients undergoing major (non-)cardiac
surgery the efﬁcacy of remote ischemic preconditioning
(RIPC) remains unclear. Some randomized controlled trials
showed a reduction in surgery related acute kidney injury
(AKI),1,2 whereas others could not conﬁrm this.3,4
Regarding the use of remote ischemic preconditioning in
patients receiving intravascular contrast media, we feel
that there is now suggestive evidence that remote
ischemic preconditioning when added to hydration may
prevent CIN.5,6 However, the routine use of added RIPC in
unselected patients cannot be advocated, and better
identiﬁcation of high risk patients is needed. Since hy-
dration is proven to be effective in preventing CIN, and
dehydration is associated with higher risk of AKI we would
argue against the use of ischemic preconditioning alone in
such high risk patients. However, we envisage that RIPC
alone may be sufﬁcient to prevent CIN in intermediate risk
patients, and could be used to replace intravenous sodium
chloride or intravenous sodium bicarbonate. Controlled
studies are needed to explore the best strategies for the
prevention of CIN.
REFERENCES
1 Zarbock A, Schmidt C, Van Aken H, Wempe C, Martens S,
Zahn PK, et al. Effect of remote ischemic preconditioning on
kidney injury among high risk patients undergoing cardiac sur-
gery: a randomized clinical trial. JAMA 2015;313(21):2133e41.
2 Ali ZA, Callaghan CJ, Lim E, Ali AA, Nouraei SA, Akthar AM, et al.
Remote ischemic preconditioning reduces myocardial and renal
injury after elective abdominal aortic aneurysm repair: a ran-
domized controlled trial. Circulation 2007;116(Suppl 11):I98e
105.
3 Gallagher SM, Jones DA, Kapur A, Wragg A, Harwood SM,
Mathur R, et al. Remote ischemic preconditioning has a neutral
effect on the incidence of kidney injury after coronary artery
bypass graft surgery. Kidney Int 2015;87(2):473e81.
4 Walsh SR, Sadat U, Boyle JR, Tang TY, Lapsley M, Norden AG,
et al. Remote ischemic preconditioning for renal protection
during elective open infrarenal abdominal aortic aneurysm
repair: randomized controlled trial. Vasc Endovascular Surg
2010;44(5):334e40.
5 Menting TP, Sterenborg TB, de Waal Y, Donders R, Wever KE,
Lemson MS, et al. Remote ischemic preconditioning to reduce
contrast-induced nephropathy: a randomized controlled trial.
Eur J Vasc Endovasc Surg 2015;50(4):527e32.
6 Er F, Nia AM, Dopp H, Hellmich M, Dahlem KM, Caglayan E, et al.
Ischemic preconditioning for prevention of contrast medium-
induced nephropathy: randomized pilot RenPro Trial (Renal
Protection Trial). Circulation 2012;126(3):296e303.
Correspondence 541M.C. Warlé*, T. Menting
Department of Surgery, Radboudumc, Nijmegen,
The Netherlands
J.F. Wetzels
Department of Nephrology, Radboudumc, Nijmegen,
The Netherlands
*Corresponding author. Department of Surgery, internal
routing 618, Radboudumc, Geert Grooteplein zuid 10,
6525 GA Nijmegen, The Netherlands.
Email-address: Michiel.Warle@radboudumc.nl (M.C. Warlé)
 2015 European Society for Vascular Surgery. Published by
Elsevier Ltd. All rights reserved.
http://dx.doi.org/10.1016/j.ejvs.2015.06.026
DOI of original article: http://dx.doi.org/10.1016/
j.ejvs.2015.04.002Re: ‘Endovascular Treatment of Ruptured Abdominal
Aortic Aneurysms with Hostile Aortic Neck Anatomy’
We read with great interest the article by Broos and col-
leagues.1 The authors reported encouraging outcomes of
EVAR in ruptured AAAwith hostile aortic neck anatomy (HNA).
We congratulate them for such a wonderful result, which may
broaden the selection criteria of the current endovascular
strategy to include patients previously excluded from EVAR.
As the authors advocated, it is technically feasible and safe
to perform EVAR in rupture AAA with HNA at experienced
endovascular centres. However, their results may not be
generalisable to less experienced centres, and they did not
tell inexperienced surgeons what to do under these cir-
cumstances. Previously, Brownrigg and colleagues2 reported
that endovascular aneurysm sealing (EVAS) is effective for
AAA with challenging aortic anatomy, which seems suitable
for treating a greater proportion of patients than EVAR. As
stent length is the only sizing variation, EVAS is of beneﬁt in
the emergency setting for ruptured aneurysm repair.3
Ruptured AAA with HNA can be repaired by experienced or
inexperienced surgeons with the revolutionary EVAS.
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We would like to thank Zhou et al. for sharing their views
on the treatment of ruptured abdominal aortic aneurysms
(rAAAs) with hostile infrarenal aortic neck anatomy. The
current EVAR devices have proven their safety and efﬁ-
cacy, in both highly specialized and less experienced
centers. In contrast, the endovascular aneurysm sealing
(EVAS) technique is relatively new and information on
intra- and post-operative complications is sparse. For this
reason we feel that great care should be taken in emer-
gency use.
The ﬁrst real world EVAS registry data have only been
published recently.1 These data consist of selected patients
treated in internationally renowned vascular centers.
Technical success is promising, but secondary interventions
were required in 9% of patients within 12 months. These
clinical failures were associated with patient selection and
deployment techniques. Current literature on EVAS for
rAAA treatment consists of a mere nine patients.1e4 All
patients were treated in large vascular centers with sub-
stantial elective EVAS experience.
In addition, endobag ﬁlling in EVAS is performed under
pressure monitoring of 180e220 mmHg, which allows the
correct dosage of the polymer to seal the aneurysm.
Theoretically, this pressure guided strategy could increase
the aortic tear in a rAAA.
Although EVAS proposes sizing beneﬁts, experience in
“less experienced hands” is not available. In contrast, there
is extensive experience with standard EVAR devices in
treating rAAA. While EVAS aims at treating hostile anatomy,
the current instructions for use are the same as those
applied in our patients.
We feel that it is too early to speculate on the use of
EVAS for rAAA, especially in hostile anatomy and most
certainly by less experienced operators. In our opinion, the
emergency outside IFU use of any device should only be
